|
Highlights from the Annual Meeting of the American Association for Cancer Research (AACR) 2025 | |
This year the annual meeting of the American Association for Cancer Research (AACR) was held from April 25-30, 2025 in Chicago, Illinois at the McCormick Place.
Without a doubt, this year's meeting confirmed the progress in the 'War on Cancer' with cutting-edge science and medicine, and presented significant advancements in the field of antibody-drug conjugates (ADCs), with a strong focus on novel targets, bispecific and dual-payload ADCs, and emerging technologies.
The annual meeting also highlighted the importance of patient advocacy and the need for more funding for cancer research.
Follow the links to the annual meeting program highlights.
|
AACR 2025: Cancer-related Fatigue and Depression
Results from a retrospective study demonstrates that female cancer survivors were 69% more likely to experience cancer-related fatigue (CRF; odds ratio [OR] = 1.69; 95% CI = 1.24–2.31; P < .001) and 58% more likely to experience depression than male survivors (OR = 1.58; 95% CI = 1.10–2.26; P = .014).
|
Preclinical Combination Data for the PROTAC BCL5 Degrader | Data from preclinical combination studies of ARV-393, an investigational orally bioavailable PROteolysis TArgeting Chimera (PROTAC) B-cell lymphoma 6 protein (BCL6) degrader being developed by Arvinas, and presented at the annual meeting of the American Association for Cancer Research (AACR), held April 25-30, 2025, in Chicago, Illinois, demonstrated synergistic anti-tumor activity, including complete regressions, in combination with Standard-of-Care (SOC) chemotherapy, SOC biologics, and investigational oral small molecule inhibitors (SMIs) in high grade B-cell lymphoma (HGBCL) and aggressive diffuse large B-cell lymphoma (DLBCL) models |
| The Conference Coverage in ADC Review | J. Antibody-drug Conjugates and Onco'Zine is made possible by our sponsors and advertisers. | | |
AACR 2025: China is Leading the Way in ADC Development
| | | | | Among the may international attendees, attending the annual meeting of the American Association for Cancer Research (AACR)find representatives of multiple Chinese biotech companies demonstrating the diversity and cutting-edge advancements innovations in the development of novel antibody-drug conjugates (ADC) | | |
AACR 2025 Reeatment Guided by Both Tissue + Liquid Biopsies led to Better Outcomes
| | |
While decision-making for genomics-driven therapy in patients with advanced, recurrent and/or metastatic, solid tumors is generally guided by results from a tissue biopsy, a question remained if a liquid biopsy, testing for circulating tumor DNA (ctDNA) for the genomic profiling of solid cancers could be beneficial.
Which method would yield more accurate results and benefit treatment decision-making? To answer the question, scientists in Italy developed a study to evaluate the efficacy (i.e overall response rate Objective Response Rate/ORR) of targeted therapy vs Standard of Care in patients with progressive disease of breast cancer, metastatic gastro-intestinal tumors, non small cell lung cancer (NSCLC) or others.
| | |
AACR 2025: An Artificial Intelligence-based Model may help Improve Pediatric Sarcoma Subtyping | |
Results from a study presented at the annual meeting of the American Association for Cancer Research (AACR), held April 25-30, 2025, in Chicago, Illinois, suggests that an artificial intelligence (AI)-based model accurately classified pediatric sarcomas using digital pathology images alone.
Pediatric sarcomas are a heterogeneous group of tumors accounting for approximately 10% of childhood solid tumors. This is a rare type of diverse tumors that can form in various types of soft tissue, including muscle, tendons, fat, blood or lymphatic vessels, nerves, or the tissue surrounding joints. Sarcomas are classified into subtypes based on several factors, including the tissue of origin and various molecular features.
| | | |
U.S. FDA Clears Investigational New Drug Application for a Phase 1/2 Study of OBI-902, a TROP2 Targeting ADC " ADC Review | |
The U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for OBI-902, a Trophoblast cell surface antigen 2 (TROP2-) targeting ADC (see ADC Drugmap) being developed by OBI Pharma.
Based on this clearance, the company plans to enroll patients with advanced solid tumors in a Phase 1/2 study This IND clearance represents a significant milestone for OBI-902, bringing forward a potentially best-in-class TROP2-targeted cancer therapy for patients with high unmet medical needs.
| | | | |
Join us as as Conference Coverage Sponsor
Conference Coverage offers a broad brand exposure across multiple channels including exclusive placement on our conference/meeting specific landing pages, newsletters, along with podcasts and video interviews and specialty online channels during the select conference.
Conference Coverage Sponsorships are available on Onco'Zine, ADC Review | Journal of Antibody-drug Conjugates, Beyond Cancer, and the 'Changing Strategies' video series.
| | |
ADC Review | J. Antibody-drug Conjugates and Onco'Zine |
| | | |
